TY  - JOUR
AU  - Escobar Cervantes, Carlos
AU  - Martí-Almor, Julio
AU  - Cabeza, Alejandro Isidoro Pérez
AU  - Bowrin, Kevin
AU  - Llorac Moix, Aleix
AU  - Genís Gironès, Mar
AU  - Gasche, David
AU  - Millier, Aurélie
AU  - Tardu, Jean
AU  - Toumi, Mondher
AU  - Briere, Jean-Baptiste
PY  - 2022
DO  - 10.1371/journal.pone.0266658
UR  - http://hdl.handle.net/10668/20425
T2  - PloS one
AB  - A Markov model was adapted to assess the real-world cost-effectiveness of rivaroxaban, dabigatran and apixaban. Each of these non-vitamin K antagonist oral anticoagulants was compared with vitamin K antagonist for stroke prevention in patients with...
LA  - en
KW  - Administration, Oral
KW  - Anticoagulants
KW  - Atrial Fibrillation
KW  - Cost-Benefit Analysis
KW  - Dabigatran
KW  - Humans
KW  - Pyridones
KW  - Rivaroxaban
KW  - Spain
KW  - Stroke
KW  - Vitamin K
TI  - Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain.
TY  - research article
VL  - 17
ER  -